• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL.

作者信息

Epperly Rebecca, Shulkin Barry L, Bag Asim K, Cheng Cheng, Inaba Hiroto, Lucas John T, Naik Swati, Triplett Brandon M, Gottschalk Stephen, Talleur Aimee C

机构信息

Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN.

Department of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN.

出版信息

Blood Adv. 2023 Oct 24;7(20):6320-6324. doi: 10.1182/bloodadvances.2023010461.

DOI:10.1182/bloodadvances.2023010461
PMID:37595052
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10589782/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d8/10589782/5c1925d224ee/BLOODA_ADV-2023-010461-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d8/10589782/dc1df2bc7c08/BLOODA_ADV-2023-010461-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d8/10589782/5c1925d224ee/BLOODA_ADV-2023-010461-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d8/10589782/dc1df2bc7c08/BLOODA_ADV-2023-010461-ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45d8/10589782/5c1925d224ee/BLOODA_ADV-2023-010461-gr1.jpg

相似文献

1
CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL.CD19嵌合抗原受体T细胞疗法对患有B细胞急性淋巴细胞白血病的儿科患者的髓外疾病显示出活性。
Blood Adv. 2023 Oct 24;7(20):6320-6324. doi: 10.1182/bloodadvances.2023010461.
2
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.在接受鼠源 CD19 CAR-T 治疗后复发或失败的复发/难治性 B-ALL 患者中使用人源化 CD19 CAR-T 细胞。
BMC Cancer. 2022 Apr 12;22(1):393. doi: 10.1186/s12885-022-09489-1.
3
Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.序贯不同 B 细胞抗原靶向 CAR T 细胞疗法治疗儿科难治/复发伯基特淋巴瘤。
Blood Adv. 2022 Feb 8;6(3):717-730. doi: 10.1182/bloodadvances.2021004557.
4
Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.两名成年伯基特淋巴瘤患者接受抗CD19嵌合抗原受体T细胞疗法后实现持久缓解：单中心经验
Leuk Lymphoma. 2022 Oct;63(10):2469-2473. doi: 10.1080/10428194.2022.2076853. Epub 2022 Jun 9.
5
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.嵌合抗原受体修饰的 T 细胞免疫疗法治疗复发/难治性成人伯基特淋巴瘤。
Front Immunol. 2022 May 20;13:879983. doi: 10.3389/fimmu.2022.879983. eCollection 2022.
6
Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.嵌合抗原受体 T 细胞疗法治疗小儿 B-ALL：缩小早期和长期结局之间的差距。
Front Immunol. 2020 Aug 11;11:1985. doi: 10.3389/fimmu.2020.01985. eCollection 2020.
7
Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.在一项针对小儿急性淋巴细胞白血病的 I 期研究中，证明了移植的嵌合抗原受体修饰的 CD19 特异性 T 细胞具有持久的抗 CD19 活性。
Hematol Oncol. 2019 Dec;37(5):601-608. doi: 10.1002/hon.2672. Epub 2019 Sep 15.
8
[How I manage B cell lymphoma patients treated with CD19 specific CAR-T cell throughout whole-process management].[我如何在整个治疗过程中管理接受CD19特异性嵌合抗原受体T细胞治疗的B细胞淋巴瘤患者]
Zhonghua Xue Ye Xue Za Zhi. 2022 Mar 14;43(3):197-202. doi: 10.3760/cma.j.issn.0253-2727.2022.03.003.
9
Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia.嵌合抗原受体 T 细胞治疗 B 细胞急性淋巴细胞白血病的临床经验。
Best Pract Res Clin Haematol. 2021 Sep;34(3):101305. doi: 10.1016/j.beha.2021.101305. Epub 2021 Aug 27.
10
Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.CD22/CD19 嵌合抗原受体 T 细胞疗法治疗累及胃肠道的复发/难治性侵袭性 B 细胞淋巴瘤患者的疗效和毒性。
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13.

引用本文的文献

1
Chimeric antigen receptor therapy for hematological malignancies: a pediatric perspective from leukapheresis to infusion.血液系统恶性肿瘤的嵌合抗原受体疗法：从小儿视角看从白细胞单采到输注的过程
Blood Transfus. 2025 Sep-Oct;23(5):443-460. doi: 10.2450/BloodTransfus.952. Epub 2025 Apr 16.
2
Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy.CD19嵌合抗原受体T细胞疗法治疗后儿童及青年急性淋巴细胞白血病髓外复发的治疗方法及预后
Blood Adv. 2025 Jan 28;9(2):354-359. doi: 10.1182/bloodadvances.2024014518.
3
Case report: sub-clinical extramedullary B-ALL in the setting of relapse following targeted therapy.

本文引用的文献

1
CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study.CD19 CAR T 细胞治疗伴有中枢神经系统活动的小儿复发急性淋巴细胞白血病：一项回顾性国际研究。
Leukemia. 2022 Jun;36(6):1525-1532. doi: 10.1038/s41375-022-01546-9. Epub 2022 Apr 25.
2
Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL.输注后 CD8+ CD19-CAR T 细胞的优先扩增与儿科 B-ALL 患者结局的疾病负担的关系。
Blood Adv. 2022 Nov 8;6(21):5737-5749. doi: 10.1182/bloodadvances.2021006293.
3
Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation.
病例报告：靶向治疗后复发时亚临床髓外 B-ALL。
Front Immunol. 2024 Sep 25;15:1423487. doi: 10.3389/fimmu.2024.1423487. eCollection 2024.
4
CAR-T cell therapy embarks on autoimmune disease.嵌合抗原受体T细胞（CAR-T）疗法开始应用于自身免疫性疾病。
Bone Marrow Transplant. 2025 Jan;60(1):6-9. doi: 10.1038/s41409-024-02429-6. Epub 2024 Oct 8.
接受免疫效应细胞治疗或造血细胞移植的儿科患者的细胞因子释放综合征及相关急性毒性
Front Oncol. 2022 Mar 24;12:841117. doi: 10.3389/fonc.2022.841117. eCollection 2022.
4
Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas.在 B 细胞非霍奇金淋巴瘤中应用辐射与嵌合抗原受体 T 细胞治疗。
Curr Treat Options Oncol. 2022 Jan;23(1):89-98. doi: 10.1007/s11864-021-00935-z. Epub 2022 Feb 15.
5
Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy.B-ALL 中的髓外疾病特征及 CAR-T 细胞治疗应答。
Blood Adv. 2022 Apr 12;6(7):2167-2182. doi: 10.1182/bloodadvances.2021006035.
6
Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report.商业用 tisagenlecleucel 治疗儿童和青年 B 细胞淋巴母细胞白血病后的疾病负担对结果的影响：儿科嵌合抗原受体联盟报告。
J Clin Oncol. 2022 Mar 20;40(9):945-955. doi: 10.1200/JCO.20.03585. Epub 2021 Dec 9.
7
Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.高疾病负担对接受Tisagenlecleucel 治疗的儿童 B-ALL 患者生存的影响。
Transplant Cell Ther. 2022 Feb;28(2):73.e1-73.e9. doi: 10.1016/j.jtct.2021.11.019. Epub 2021 Dec 4.
8
Other (Non-CNS/Testicular) Extramedullary Localizations of Childhood Relapsed Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma-A Report from the ALL-REZ Study Group.儿童复发性急性淋巴细胞白血病和淋巴细胞淋巴瘤的其他（非中枢神经系统/睾丸）髓外定位——来自ALL-REZ研究组的报告
J Clin Med. 2021 Nov 14;10(22):5292. doi: 10.3390/jcm10225292.
9
Minimal Residual Disease Prior to and After Haematopoietic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia: What Level of Negativity Is Relevant?儿童和青少年急性淋巴细胞白血病造血干细胞移植前后的微小残留病：何种阴性水平具有相关性？
Front Pediatr. 2021 Nov 5;9:777108. doi: 10.3389/fped.2021.777108. eCollection 2021.
10
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium Report.Tisagenlecleucel 治疗复发/难治性髓外 ALL 疗效：儿科真实世界 CAR 联盟报告。
Blood Adv. 2022 Jan 25;6(2):600-610. doi: 10.1182/bloodadvances.2021005564.